Brian Wolpin Celebrates FDA Approval of Daraxonrasib in Pancreatic Cancer as the Future of the Field
-
September 30, 2026
September 30, 2026
September 30, 2026
October 7, 2026
Breast cancer management is becoming increasingly biology-driven, with treatment decisions extending well beyond anatomic stage and conventional receptor classification.
The evolution of breast cancer care is increasingly challenging a long-standing assumption in oncology: that greater treatment intensity necessarily translates into better outcomes.